Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E6.59 EPS (ttm)6.18 Insider Own- Shs Outstand2.46B Perf Week-0.73%
Market Cap100.24B Forward P/E16.13 EPS next Y2.52 Insider Trans- Shs Float2.43B Perf Month-1.13%
Income14.90B PEG0.80 EPS next Q0.52 Inst Own9.20% Short Float0.15% Perf Quarter0.17%
Sales36.18B P/S2.77 EPS this Y-48.90% Inst Trans-3.77% Short Ratio0.97 Perf Half Y-5.72%
Book/sh3.38 P/B12.04 EPS next Y8.28% ROA19.10% Target Price45.67 Perf Year-7.09%
Cash/sh3.65 P/C11.14 EPS next 5Y8.20% ROE163.80% 52W Range36.72 - 47.14 Perf YTD0.61%
Dividend2.33 P/FCF- EPS past 5Y-12.20% ROI15.00% 52W High-13.67% Beta0.86
Dividend %5.72% Quick Ratio1.00 Sales past 5Y-4.10% Gross Margin67.50% 52W Low10.84% ATR0.61
Employees98702 Current Ratio1.30 Sales Q/Q8.50% Oper. Margin50.40% RSI (14)52.52 Volatility1.08% 1.12%
OptionableYes Debt/Eq3.04 EPS Q/Q32.00% Profit Margin40.80% Rel Volume0.76 Prev Close40.39
ShortableYes LT Debt/Eq2.78 EarningsOct 28 Payout39.70% Avg Volume3.85M Price40.70
Recom2.50 SMA20-1.31% SMA501.20% SMA200-4.06% Volume2,927,127 Change0.77%
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Nov-24-09Initiated Leerink Swann Mkt Perform
Nov-16-09Initiated Deutsche Securities Hold
Nov-12-09Initiated Barclays Capital Equal Weight
Oct-23-09Downgrade Jefferies & Co Buy → Hold
Mar-17-09Initiated Credit Suisse Outperform
Nov-26-15 03:30AM  Why GlaxoSmithKline PLC & Hogg Robinson PLC Provide Terrific Value For Money!
Nov-25-15 11:35PM  GSK in China: escaping the shadow of a scandal Reuters
05:01PM  Valeant, Glaxo, Novartis Skin Drug Prices Have Soared at Investor's Business Daily
09:53AM  EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Nov-24-15 08:38AM  Healthcare's Greatest Dividend Stocks at Motley Fool
04:32AM  Why GlaxoSmithKline plc Might Be Worth £20!
Nov-23-15 11:20AM  3 High-Risk Dividend Stocks to Avoid at Motley Fool
11:15AM  Idera shares jump on new partnership with GSK for kidney disease drugs at
10:08AM  Existing Drugs for Renal Cell Carcinoma
07:22AM  Are GlaxoSmithKline plc & AstraZeneca plc Really On The Road To Recovery?
Nov-21-15 09:13AM  Is Vodafone Group Plc (ADR) (VOD) Going to Burn These Hedge Funds? at Insider Monkey
12:01AM  [$$] Biotech's Biggest Battle at
Nov-20-15 01:47PM  UK Retail Sales Fall Unexpectedly
11:43AM  [$$] How GlaxoSmithKline Can Revive Its Share Price at The Wall Street Journal
10:43AM  Studies Supporting Opdivos sBLA for Renal Cell Carcinoma
10:42AM  Opdivos sBLA Accepted by FDA for Priority Review
Nov-19-15 10:46AM  Is GlaxoSmithKline plc The Next Tesco PLC?
09:16AM  5 Things GlaxoSmithKline PLC Wants You to Know at Motley Fool
08:25AM  4 Large Cap, Blue Chip Stocks That Pay a 5% Dividend or More at 24/7 Wall St.
Nov-18-15 11:50PM  An Indian yoga guru is building one of the countrys biggest consumer goods companies
06:00AM  How to Prepare for BioMarin's (and Biotech's) Biggest Event of 2015 at TheStreet
03:10AM  Should You Invest In Dividend Delights GlaxoSmithKline plc, British American Tobacco plc & Persimmon plc?
Nov-17-15 11:50AM  Fast-growing specialty pharma firm Egalet Corp. hires first general counsel at
10:53AM  Is The FTSE 100 A Better Bet For Dividend Growth Than Pearson plc Or GlaxoSmithKline plc?
07:50AM  Why Theravance Inc. Vaulted 15% Higher in October at Motley Fool
Nov-16-15 10:00AM  GSK Has The Nerve To Innovate Medicine at Forbes
08:45AM  Should You Buy GlaxoSmithKline plc, Diploma PLC & Merlin Entertainments PLC?
Nov-15-15 03:00PM  Alnylam Pharmaceuticals, Inc. Earnings: 100% Positive (Data) at Motley Fool
04:03AM  Beginners' Portfolio Ahead, Despite Being Held Back By BP plc, Rio Tinto plc And GlaxoSmithKline plc
Nov-14-15 07:01AM  Better Dividend Stock: Pfizer vs. GlaxoSmithKline at Motley Fool
Nov-13-15 12:39PM  5 Reasons Roche Thinks It Can Outclass the Competition at Motley Fool
Nov-12-15 05:08PM  Defensive Investing: Learn from a Hedge Fund Pro at Investopedia
09:03AM  Market-Topping Q3 Results and Positive Wall Street Commentary Give GlaxoSmithKline a Boost in October at Motley Fool
05:04AM  Are Predators Circling GlaxoSmithKline plc?
Nov-11-15 10:58AM  Merck & Co. Is Growing despite Its Revenue Falling in 3Q15
04:18AM  Are Royal Dutch Shell Plc, GlaxoSmithKline plc & Imperial Tobacco Group PLC Perfect For Income Seekers?
Nov-10-15 02:12PM  Isis Posts Narrower-than-Expected Loss in Q3, Shares Up
Nov-09-15 05:56PM  Glaxo plans up to 20 new drug applications AAP
01:37PM  Regulus Was Last Weeks Top Biotech Performer
11:00AM  Are GlaxoSmithKline plc, BAE Systems plc And Rexam PLC Brilliant Bargains Or Value Traps?
08:39AM  [$$] GlaxoSmithKline Extends Avalon Partnership at The Wall Street Journal
08:00AM  GSK, COPD Foundation and AARC Team Up for #COPDChat, November 9th, 12 pm ET PR Newswire
Nov-08-15 11:24AM  6 Dividend Stocks Investors Love Right Now at TheStreet
Nov-06-15 02:15PM  Amec Foster Wheelers Steep Fall Pushed Down Energy Sector, EWU
11:00AM  Sanofi/GSK: across the channel at Financial Times
10:14AM  What Were Pfizers Other Key Developments in 3Q15?
Nov-05-15 05:58PM  Focus on Health Care Savings: 5 Generic Drug Stocks to Buy
10:46AM  GlaxoSmithKline's R&D Vision Needs More Vision at Bloomberg
10:25AM  ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray
10:17AM  Allergan exhibits singular approach to potential merger at Financial Times
10:11AM  Which Pfizer Products Saw Negative Growth in 3Q15?
08:30AM  Why I'm Going Long One Of The Most Controversial Stocks On The Market
Nov-04-15 06:52PM  FDA Approves GlaxoSmithKline's Nucala as Add-on to Treat Severe Asthma at The Wall Street Journal
06:13PM  Glaxo wins US approval for drug to treat severe asthma
06:06PM  FDA approves GSK's drug Nucala for severe asthma Reuters
04:40PM  Gates Foundation, GSK, others back biotech in white-hot area of cancer at
Nov-03-15 08:15PM  PRESS DIGEST- British Business - Nov 4 Reuters
05:06PM  Glaxo CEO Witty: More Transparency Needed in Drug Pricing
04:37PM  Glaxo plans up to 20 new drug applications in near term
03:10PM  GSK CEO: Novartis deal is only deal we need
03:10PM  GSK CEO: Drug debate 'overly focused' on price
01:29PM  J&J, ViiV: 2 injections every month or 2 could control HIV
12:17PM  GSK plan to file up to 20 new drugs by 2020 underwhelms market
10:09AM  How Gilead Sciences Is Strengthening Its Presence in HIV Segment
10:00AM  GlaxoSmithKline expects to seek approval for 20 products by 2020 at
09:56AM  GSK unveils new drugs to boost growth at Financial Times
09:15AM  GlaxoSmithKline (GSK) Stock Prepares to Rally, Shares Could Advance 25% at TheStreet
08:34AM  Johnson & Johnson HIV combination succeeds in mid-stage study Reuters
08:24AM  ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy PR Newswire
07:37AM  GSK boss silent on report drugmaker rebuffed Pfizer
07:15AM  Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK PR Newswire
07:09AM  ViiV Healthcare Attacking, but Gilead Prepares to Strike Back at Motley Fool
07:08AM  Glaxo to Submit 20 New Drugs Within Five Years, Repeats Forecast at Bloomberg
07:05AM  GSK aims to file up to 20 new drugs for approval by 2020
06:13AM  Is GlaxoSmithKline plc Capable Of 20%+ Returns?
Nov-02-15 06:09PM  Pfizer spurned by GSK before Allergan talks at Financial Times
08:51AM  One thing Ackmans right about drug companies survive billions in fines at MarketWatch
Nov-01-15 02:00AM  Drugged up: GSK, Roche and Sanofi to set out their stalls
Oct-30-15 03:51PM  Pfizers Acquisition Quest - Is Allergan A Safer Bet Than Glaxo?
02:45PM  A Shake-Up Is Coming In Big Pharma -- Here's How To Profit
10:16AM  GlaxoSmithKline Plc Earnings Q3, 2015
09:10AM  Why Earnings Are Set To Launch At GlaxoSmithKline plc, Crest Nicholson Holdings PLC And British American Tobacco plc
09:07AM  ISIS Rose 11.4%, Helped the Biotechnology Subgroups Performance
06:51AM  Pro's top three bargain stocks
Oct-29-15 04:07PM  GlaxoSmithKline's Diverging Q3 Results Imply a Long Road to Recovery at Motley Fool
02:51PM  The 10 Highest Dividend Health Care Stocks Are Not All Buys at TheStreet
02:01PM  GSK falls on dented takeover hopes at Financial Times
01:39PM  Allergan Isn't Pfizer's Best Option
01:19PM  Theravance's Q3 Loss Wider than Expected, Revenues Miss
09:06AM  Glaxo Up on Q3 Earnings Beat, Revenues Rise, Outlook Same
Oct-28-15 08:56PM  PRESS DIGEST- Financial Times - Oct 29
12:14PM  Should GlaxoSmithKline plc Be Broken Up, As Neil Woodford Urges?
11:29AM  Don't bank on U.S. drug price rises, warns GSK boss Reuters
11:02AM  HIV drugs and vaccines help GSK beat forecasts at Financial Times
10:31AM  GlaxoSmithKline beats forecasts as HIV drugs, flu vaccines shine
10:23AM  [$$] GlaxoSmithKline Reports Higher Sales at The Wall Street Journal
09:53AM  Reuters Business News Schedule at 1330 GMT/0930 AM ET
09:29AM  Glaxo (GSK) Tops Q3 Earnings, Revenues Up Y/Y
09:20AM  GlaxoSmithKline profits rise 34 percent
08:08AM  HIV drugs and flu vaccines help GlaxoSmithKline beat forecasts
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc has a collaboration agreement with Universit de Sherbrooke to develop a medicine for patients with iron overload disorders, such as beta-thalassemia or hereditary hemochromatosis; and Pfizer Inc. for the development of portable, continuous, miniature, and modular (PCMM) prototype for oral solid dose (OSD) pharmaceutical development and manufacturing. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerMay 11Buy14.00365,1065,111,484365,106May 13 12:36 PM
GLAXOSMITHKLINE PLC10% OwnerMar 02Buy18.0692,6741,673,69231,673,853Mar 02 03:45 PM